News

MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1), an immunomodulatory enzyme, is required for the effective triggering of an immune response. However, dysregulation of MALT1 is also associated

Atlas joins previous seed investors Forbion Capital Partners (Forbion) and Omega Funds (Omega) as investors in this funding round. Replimune, headquartered in Oxford UK and with a significant

The Clinical Trial Application (CTA) for XEN801 was accepted by Health Canada and the first patient has been dosed in the Phase 1 clinical trial. If supported by

Mylan, Amneal Pharmaceuticals, Roxane Laboratories, Actavis and Sandoz had filed abbreviated new drug applications (ANDAs) to market generic versions of Vyvanse. Following the drug makers’ plan to create

The institute granted the funding under its CIRM 2.0 program, which is designed to speed up the development of stem cell-based treatments for people with unmet medical requirements.

In its final draft guidance, the regulator recommended Zydelig for patients whose leukaemia has come back less than two years following earlier treatment. Earlier this year, NICE asked

The European Medicines Agency’s Committee for Medicinal Products for Human Use gives its recommendations for marketing authorization to drugs to the European Commission (EC). The commission is expected

These studies are expected to be completed within the next two months. These studies are anticipated to produce purified recombinant protein and conduct an orthogonal assay to validate

A United States patent entitled "Erythrocytes Containing Arginine Deiminase" has been issued by the U.S. Patent and Trademark Office (USPTO) as U.S. Patent No. 9,125,876. It covers the